MHPRA

(redirected from Medicines and Healthcare products Regulatory Agency)
Also found in: Dictionary, Medical, Wikipedia.
AcronymDefinition
MHPRAMedicines and Healthcare Products Regulatory Agency (UK)
References in periodicals archive ?
The company awaits issue of the formal Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency in the coming weeks, with UK launch expected to be this autumn.
The Medicines and Healthcare products Regulatory Agency (MHRA) published the companyled recall for medicines purchased since September.
The Medicines and Healthcare Products Regulatory Agency's John Wilkinson said: "This man is a criminal and all he wants to do is take money from vulnerable people.
Zheng Tian Wan herbal pills contain aconite, a poisonous plant which can be toxic to the heart and the nervous system and can cause death, said the Medicines and Healthcare products Regulatory Agency.
But the new Medicines and Healthcare products Regulatory Agency guidance advises lower doses for all children under four.
The Medicines and Healthcare products Regulatory Agency (MHRA) issued a drug alert about a batch of 300ml bottles of Metatone Tonic.
A review of popular remedies such as Lemsip powders, Day Nurse and Sudafed by the Medicines and Healthcare products Regulatory Agency found "no robust evidence that these medicines work" in children.
(NASDAQ: TARO) has reported that Taro Pharmaceuticals (UK) Limited (Taro UK), its affiliate in the United Kingdom, has been granted a marketing authorization for Etopan XL Tablets 600 mg, Etodolac (Etopan XL) by the Medicines and Healthcare Products Regulatory Agency, the UK equivalent of the U.S.
The Medicines and Healthcare products Regulatory Agency said it had become aware of the slimming aids being available on the market in this country.
The medicines and healthcare products regulatory agency is looking to place a contract for back-up workplace mediation services.
United States-based Galera Therapeutics has received a Promising Innovative Medicines (PIM) designation for its GC4419 from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA), it was reported yesterday.
It was reported yesterday that Sanofi, a France-based pharmaucetical company, has received a positive scientific opinion through the Early Access to Medicines Scheme from the UK's Medicines and Healthcare Products Regulatory Agency for dupilumab, an investigational treatment for atopic dermatitis.